Viking Therapeutics Emerges as Prime Acquisition Target in Weight-Loss Drug Race

The biotech sector’s attention is firmly fixed on Viking Therapeutics as the company prepares for a featured presentation at the prestigious Stifel Healthcare Conference in New York. Management is scheduled to participate in a fireside chat between 10:40 PM and 11:10 PM German time, with these appearances occurring against a backdrop of intensifying merger speculation within the lucrative obesity treatment market.

Recent competitive tension between pharmaceutical giants Pfizer and Novo Nordisk, who are both pursuing biotechnology firm Metsera, has significantly heightened merger and acquisition activity around GLP-1 medications. Industry observers now position Viking Therapeutics as the next potential major acquisition candidate. The company’s shares surged as much as 5% during yesterday’s Read more...